Single Lipiflow Treatment to Reduce Pharmacologic Burden in DED (NCT06542276) | Clinical Trial Compass
By InvitationNot Applicable
Single Lipiflow Treatment to Reduce Pharmacologic Burden in DED
United States30 participantsStarted 2023-09-01
Plain-language summary
Purpose: To evaluate the efficacy of vectored thermal pulsation treatment in subjects with a history of dry eye disease currently using a topical immunomodulator medication.
Who can participate
Age range25 Years – 65 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* No prior history of meibomian gland treatment procedures LipiFlow, TearCare, or I-Lux
* lifitegrast or cyclosporine eye drops daily for a period of at least one year but not exceeding five years
* Meibograpy documneted retention of at least 50% of meibomian glands.
Exclusion Criteria:
* evidence of meibomian gland dropout exceeding 50%
* ocular rosacea,
* ocular surgery within the preceding three months
* prior in-office thermal meibomian gland treatment
* ocular trauma within preceding three months
* ocular herpetic infection
* chronic or recurrent inflammation
* eyelid abnormalities affecting lid function ocular surface abnormalities compromising corneal integrity (eg, epithelial basement membrane dystrophy, corneal burn)
* pregnant
What they're measuring
1
Number of Subjects discontinuing Topical Immunomodulator use